Where does Dicerna Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Dicerna Pharmaceuticals, Inc. ranks #3,837 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Dicerna Pharmaceuticals, Inc. hold?

Dicerna Pharmaceuticals, Inc. holds 94 US utility patents granted between 2015 and 2025, spanning 14 technology areas.

What is Dicerna Pharmaceuticals, Inc.'s Innovation Score?

Dicerna Pharmaceuticals, Inc. has an Innovation Score of 54.4 out of 100 (top 8% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Dicerna Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Dicerna Pharmaceuticals, Inc.'s recent grant velocity is +79% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Dicerna Pharmaceuticals, Inc.'s patents?

Dicerna Pharmaceuticals, Inc.'s patents average 28.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Dicerna Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Dicerna Pharmaceuticals, Inc.

Q: What technology areas does Dicerna Pharmaceuticals, Inc. focus on?

Dicerna Pharmaceuticals, Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 93 patents. Grants appear in 14 CPC subclasses total.

USPTO PatentsView assignee record - 94 granted patents across 14 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Dicerna ranks #3,837 of 49,997 tracked US assignees by granted-patent volume, with 94 patents across 14 technology areas.

#3,837
of 49,997 US assignees by volume: Top 8%
by Innovation Score (54.4/100): 28.3
avg claims per patent: +79%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3837 · US Corporation #3,837 · 94 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 94 grants
TOP-DECILE #3,837/49,997
PHOTO-FINISH Bertec
CPC-FOCUS C12N · 14 areas
INNOV-PAR 54.4/100
CLAIMS-DENSE 28.3 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +79% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Bertec Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Basell Poliolefine… · near

54
Dicerna Pharmaceutic… · this assignee

54
Ford Motor · near

54
Pass & Seymour · near

54
Visteon Global · near

54
3D Lighting… · lowest

7

What this shows Dicerna's Innovation Score is 54.4/100 (top 8% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Dicerna's grants concentrate

Dicerna Pharmaceuticals, Inc. is a focused PatentsView assignee: 14 CPC subclasses with 98.9% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2022 (16 grants) versus a trough of 5 in 2015. By volume, Dicerna sits between Bertec Corporation and Heptagon Micro Optics Pte. Ltd..

Dicerna's three-year grant acceleration

From 2019–2021 to 2022–2024, Dicerna Pharmaceuticals, Inc. moved from 25 to 39 grants (1.56x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Bertec

94
Butamax Advanced…

94
Cygames

94
Dematic

94
East China Univer…

94
Endura Products

94
Globe Union Indus…

94
Heptagon Micro Op…

94
Dicerna Pharmaceu… ◀

94

What this shows Dicerna holds 94 patents at rank #3,837, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Dicerna

By rank, the assignees closest to #3,837 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Dicerna's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Dicerna, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (54 here).

Pass & Seymour, Inc. 54 Visteon Global Technologies, Inc. 54 Basell Poliolefine Italia S.r.l. 54 Ford Motor Company 54

Similar claim depth

Nearest assignees by average claims per patent (28.3 here).

Mc10, Inc. 28.3 avg Federated Wireless, Inc. 28.1 avg Sight Sciences, Inc. 28.0 avg Fujifilm Electronic Materials U.S.A., Inc. 28.6 avg

Dicerna's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

54 Top 8% higher than 92% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Dicerna Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	5.3%
2016	5	5.3%
2017	10	10.6%
2018	8	8.5%
2019	5	5.3%
2020	11	11.7%
2021	9	9.6%
2022	16	17.0%
2023	15	16.0%
2024	8	8.5%
2025partial year	2	2.1%

Which technologies does Dicerna Pharmaceuticals, Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 93

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 62

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 53

C12Y - Enzymes 21

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 11

Y02A - Technologies FOR Adaptation TO Climate Change 4

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 4

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 4

C07K - Peptides 3

C07D - Heterocyclic Compounds 3

C07C - Acyclic OR Carbocyclic Compounds 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 2

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Top 14 of 14 technology areas

Where it ranks

Overall rank by patents

#3,837

of 49,997 tracked assignees

Innovation Score

54.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Dicerna Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Dicerna Pharmaceuticals, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 98.9% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #3,837 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Dicerna Pharmaceuticals, Inc. against Bertec Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 54.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.